Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB) Stock Price, Analysis & Data
| Geld | n/a |
| Marktkapitalisierung | 973.61 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -207.1 Mio |
| Beta | 2.42 |
| EPS (ttm) | -1.89 |
| KGV (TTM) | n/a |
| Forward-KGV | -5.2 |
| KBV (TTM) | 2.55 |
| KUV (TTM) | n/a |
| Earnings Date | Nov 2, 2026 |
| Brief | n/a |
| Volumen | 534,944 |
| Ø Vol. (20D) | 1,613,285 |
| Eröffnung | 8.99 |
| Vortagesschluss | 9.10 |
| Tagesspanne | 8.84 - 9.14 |
| 52-Wk Range | 3.79 - 11.45 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über SLDB
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the trea...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Solid Biosciences 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -174.32 Mio, ein Anstieg von 39.8 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 3 Monaten · Insider Monkey
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged mor...
